%0 Journal Article
%A Galldiks, Norbert
%A Werner, Jan-Michael
%A Tscherpel, Caroline
%A Fink, Gereon R
%A Langen, Karl-Josef
%T Imaging findings following regorafenib in malignant gliomas: FET PET adds valuable information to anatomical MRI
%J Neuro-oncology advances
%V 1
%N 1
%@ 2632-2498
%C Oxford
%I Oxford University Press
%M FZJ-2020-01691
%P vdz038
%D 2019
%X The prospective REGOMA phase 2 trial showed an encouraging and significant median progression-free and overall survival (PFS, OS) benefit for glioblastoma patients at first progression treated with the oral multikinase inhibitor regorafenib compared to lomustine monotherapy.1 In particular, the OS benefit was 1.8 months compared to lomustine (7.4 vs. 5.6 months; P = .0009), and the hazard ratio was 0.5 (95% confidence interval, 0.33–0.75). Interestingly, despite unchanged MRI findings at first follow-up (“Stable Disease,” 39%) following regorafenib, complete or partial radiological responses according to the RANO criteria2 were only seen in 5% of cases treated with regorafenib. On the other hand, 59% of patients in the regorafenib arm had grade 3–4 adverse events.
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:32642667
%U <Go to ISI:>//WOS:000886002700031
%R 10.1093/noajnl/vdz038
%U https://juser.fz-juelich.de/record/874903